• Emmanuel Martinod, Kader Chouahnia, Dana M Radu, Pascal Joudiou, Yurdagul Uzunhan, Morad Bensidhoum, Ana M Santos Portela, Patrice Guiraudet, Marine Peretti, Marie-Dominique Destable, Audrey Solis, Sabiha Benachi, Anne Fialaire-Legendre, Hélène Rouard, Thierry Collon, Jacques Piquet, Sylvie Leroy, Nicolas Vénissac, Joseph Santini, Christophe Tresallet, Hervé Dutau, Georges Sebbane, Yves Cohen, Sadek Beloucif, Alexandre C d'Audiffret, Hervé Petite, Dominique Valeyre, Alain Carpentier, and Eric Vicaut.
• Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Seine-Saint-Denis, Hôpital Avicenne, Chirurgie Thoracique et Vasculaire, Université Paris 13, Sorbonne Paris Cité, UFR Santé, Médecine et Biologie Humaine, Bobigny, France.
• JAMA. 2018 Jun 5; 319 (21): 221222222212-2222.

ImportanceAirway transplantation could be an option for patients with proximal lung tumor or with end-stage tracheobronchial disease. New methods for airway transplantation remain highly controversial.ObjectiveTo establish the feasibility of airway bioengineering using a technique based on the implantation of stented aortic matrices.Design, Setting, And ParticipantsUncontrolled single-center cohort study including 20 patients with end-stage tracheal lesions or with proximal lung tumors requiring a pneumonectomy. The study was conducted in Paris, France, from October 2009 through February 2017; final follow-up for all patients occurred on November 2, 2017.ExposuresRadical resection of the lesions was performed using standard surgical techniques. After resection, airway reconstruction was performed using a human cryopreserved (-80°C) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. To prevent airway collapse, a custom-made stent was inserted into the allograft. In patients with proximal lung tumors, the lung-sparing intervention of bronchial transplantation was used.Main Outcomes And MeasuresThe primary outcome was 90-day mortality. The secondary outcome was 90-day morbidity.ResultsTwenty patients were included in the study (mean age, 54.9 years; age range, 24-79 years; 13 men [65%]). Thirteen patients underwent tracheal (n = 5), bronchial (n = 7), or carinal (n = 1) transplantation. Airway transplantation was not performed in 7 patients for the following reasons: medical contraindication (n = 1), unavoidable pneumonectomy (n = 1), exploratory thoracotomy only (n = 2), and a lobectomy or bilobectomy was possible (n = 3). Among the 20 patients initially included, the overall 90-day mortality rate was 5% (1 patient underwent a carinal transplantation and died). No mortality at 90 days was observed among patients who underwent tracheal or bronchial reconstruction. Among the 13 patients who underwent airway transplantation, major 90-day morbidity events occurred in 4 (30.8%) and included laryngeal edema, acute lung edema, acute respiratory distress syndrome, and atrial fibrillation. There was no adverse event directly related to the surgical technique. Stent removal was performed at a postoperative mean of 18.2 months. At a median follow-up of 3 years 11 months, 10 of the 13 patients (76.9%) were alive. Of these 10 patients, 8 (80%) breathed normally through newly formed airways after stent removal. Regeneration of epithelium and de novo generation of cartilage were observed within aortic matrices from recipient cells.Conclusions And RelevanceIn this uncontrolled study, airway bioengineering using stented aortic matrices demonstrated feasibility for complex tracheal and bronchial reconstruction. Further research is needed to assess efficacy and safety.Trial Registrationclinicaltrials.gov Identifier: NCT01331863.

31 keywords...

hide…